A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340846 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Warfarin
DRUG: Ketoconazole
DRUG: Gemfibrozil
DRUG: GSK2118436 150mg
DRUG: GSK2118436 75mg

Sponsor

GlaxoSmithKline